Healthy men needed to test new prostate cancer drug interaction
NCT ID NCT07548606
First seen May 02, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests a new prostate cancer drug called opevesostat in 14 healthy men to see how it behaves in the body when taken with or without another drug, itraconazole. The goal is to understand how the body processes opevesostat, which may help guide future dosing for prostate cancer patients. Participants will receive both drugs in a fixed order, and researchers will measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Inc. ( Site 0001)
RECRUITINGLincoln, Nebraska, 68502, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.